Circio Holding ASA - Share Issue/Capital Change 2026

Circio Holding ASA: Registration of share capital increase following exercise of options and settlement of RSUs

Oslo, 11 May 2026: Reference is made to the stock exchange announcement by

Circio Holding ASA (OSE: CRNA) (the "Company") on 6 May 2026, regarding the

board of directors' resolution to increase the share capital of the Company in

connection with the exercise of employee options and the settlement of

restricted stock units ("RSUs") pursuant to the Company's long-term incentive

program for its employees and the Company's program for RSUs for the board

members.

The share capital increase has now been registered with the Norwegian Register

of Business Enterprises (Nw. Foretaksregisteret). The Company's new share

capital is NOK 142,903,417.20, divided into 238,172,362 shares, each with a

nominal value of NOK 0.60.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Lubor Gaal, CFO

Phone: +34 683 34 3811

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA

expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic construct designed

for efficient biogenesis of multifunctional circRNA inside target cells. The

circVec platform has applications in multiple therapeutic settings, including

genetic medicine, cell therapy and chronic disease. It has demonstrated

75-fold increased RNA half-life and up to 50-fold enhanced protein expression

vs. conventional mRNA-based viral and non-viral vector systems, with the

potential to become a new gold-standard gene expression technology. The

circVec R&D activities are being conducted by the wholly owned subsidiary

Circio AB in Stockholm, Sweden.

AI assistant